STAAR Surgical Company reaffirmed sales guidance for the year 2022. For the year, the company reaffirming previously provided outlook for fiscal 2022 net sales of approximately $295 million, which takes into account a significant currency headwind and a continuation of the current level of COVID-19 related challenges in China and elsewhere, offset by stronger than expected demand for EVO lenses, which has continued through the beginning of the third quarter.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
44.93 USD | +4.23% |
|
-5.63% | +43.96% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+43.96% | 2.21B | |
-5.50% | 181B | |
-5.79% | 99.52B | |
-6.59% | 65.82B | |
-8.38% | 45.21B | |
+8.42% | 43.85B | |
+10.10% | 42.17B | |
+10.97% | 28.75B | |
+18.89% | 25.39B | |
-8.39% | 23.5B |
- Stock Market
- Equities
- STAA Stock
- News STAAR Surgical Company
- STAAR Surgical Company Re-Affirms Sales Guidance for the Year 2022